Professor Susan Clark
Garvan Insititute of Medical Research (NSW)
$353,633
2016 – 2018
The Research
Patients with estrogen receptor positive breast cancer receive endocrine therapy, however half fail to respond and relapse. Endocrine resistant cancer currently represents the most significant challenge in breast cancer treatment. We have identified an underlying molecular mechanism that determines endocrine sensitivity that we will exploit to stratify patients as responders to endocrine therapy, and use as a novel therapeutic strategy to effectively treat patients with recurrent disease.
share
.svg)
